PLUS1
145.50
0.42 (0.29%)
0.42 (0.29%)
Upgrade to Real-Time
Afterhours (Closed)
Best deals to access real time data! |
|
Big Cap Pro
Monthly Subscription
for only
|
|
Small Cap Basic
Monthly Subscription
for only
|
|
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Johnson and Johnson | JNJ | NYSE | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded  |
|
|---|---|---|---|---|
| 0.42 | 0.29% | 145.50 | 19:59:56 |
| Close Price | Low Price | High Price | Open Price | Previous Close |
|---|---|---|---|---|
| 145.24 | 144.35 | 147.47 | 145.98 | 145.08 |
| Stock Trades | Traded Volume | VWAP | Dollar Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 52,861 | 4,154,732 | $ 145.37 | $ 603,957,395 | 6,397,338 | 109.16 - 157.00 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 19:59:44 | formt | 100 | $ 145.50 | USD |
Johnson and Johnson Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 383.08B | 2.63B | 2.63B | $ 82.06B | $ 17.24B | 5.63 | 22.60 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| 11.45M | $ 3.75 | 2.58% | -29.00k | 0.10% |
Johnson and Johnson News
| Date | Time | Source | News Article |
|---|---|---|---|
| 10/23/2020 | 18:18 | Dow Jones News | Pivotal Studies of Covid-19 Vaccines From AstraZeneca, J&J.. |
| 10/23/2020 | 17:13 | Dow Jones News | Pivotal Study of J&J's Covid-19 Vaccine to Resume, Company.. |
| 10/23/2020 | 16:09 | Edgar (US Regulatory) | Quarterly Report (10-q) |
| 10/22/2020 | 14:16 | PR Newswire (US) | Johnson & Johnson Announces Quarterly Dividend for Fourth.. |
| 10/22/2020 | 05:59 | Dow Jones News | Covid-19 Vaccine Makers to Face Challenges When Recognizing.. |
| 10/20/2020 | 08:45 | NetworkNewsWire | Banking on the Next Blockbuster Drug |
| 10/16/2020 | 08:36 | Dow Jones News | J&J's Janssen Gets CHMP Positive Opinion for Tremfya in.. |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical JNJ Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 147.60 | 148.90 | 143.84 | 145.24 | 5,657,154 | -2.10 | -1.42% |
| 1 Month | 144.45 | 153.142 | 143.84 | 147.43 | 6,182,693 | 1.05 | 0.73% |
| 3 Months | 146.96 | 155.47 | 142.96 | 148.47 | 5,954,446 | -1.46 | -0.99% |
| 6 Months | 154.25 | 157.00 | 137.02 | 147.32 | 6,638,795 | -8.75 | -5.67% |
| 1 Year | 129.66 | 157.00 | 109.16 | 141.98 | 7,821,300 | 15.84 | 12.22% |
| 3 Years | 142.13 | 157.00 | 109.16 | 136.95 | 7,143,047 | 3.37 | 2.37% |
| 5 Years | 99.87 | 157.00 | 94.28 | 129.72 | 6,667,746 | 45.63 | 45.69% |
Johnson and Johnson Description
| Johnson & Johnson is the world's largest and most diverse healthcare firm. Three divisions make up the firm: pharmaceutical, medical devices and diagnostics, and consumer. The drug and device groups represent close to 80% of sales and drive the majority of cash flows for the firm. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. The device segment focuses on orthopedics, surgery tools, vision care, and a few smaller areas. The last segment of consumer focuses on baby care, beauty, oral care, over-the-counter drugs, and women's health. Geographically, just over half of total revenue is generated in the United States. |
